IQVIA HOLDINGS INC. Research and Development Expense
IQVIA HOLDINGS INC. (IQV) reported Research and Development Expense of $3.34 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2016-02-11
- IQVIA HOLDINGS INC. research and development expense for fiscal 2015 was $3.34M, a 42.38% decline from fiscal 2014.
- IQVIA HOLDINGS INC. research and development expense for fiscal 2014 was $5.79M, a 16.87% increase from fiscal 2013.
- IQVIA HOLDINGS INC. research and development expense for fiscal 2013 was $4.96M, a 52.47% decline from fiscal 2012.
- IQVIA HOLDINGS INC. research and development expense for fiscal 2012 was $10.43M, a 4.41% increase from fiscal 2011.
| Period end | Research and Development Expense 12 month |
|---|---|
| 2015-12-31 | $3.34M 10-K · filed 2016-02-11 |
| 2014-12-31 | $5.79M 10-K · filed 2016-02-11 |
| 2013-12-31 | $4.96M 10-K · filed 2016-02-11 |
| 2012-12-31 | $10.43M 10-K · filed 2015-02-12 |
| 2011-12-31 | $9.99M 10-K · filed 2014-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |